Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg

Hello, this is Tafnat
Epidemiology and Disease Burden
Transmission and Virology
Disease Course and Diagnosis of Chronic Hepattis B Virus Infection
SHOP NOW

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF)

TAFNAT 25mg

Hepatitis B Virus: Disease Background of Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg Tablet

  • Epidemiology and Disease Burden
  • Transmission and Virology
  • Disease Course and Diagnosis of Chronic Hepatitis B Virus Infection
  • Compensated Cirrhosis and Decompensated Cirrhosis with Chronic Hepatitis B 8
  • Hepatocellular Carcinoma/Liver Transplantation
  • Co-infections with Hepatitis
  • New Perspective on Treatment of Patients with Hepatitis B Infection.

Spotlight onTafnat 25mg (Tenofovir Alafenamide -TAF)- Tenofovir Alafenamide Fumarate :
As a Newer Treatment Modality in Hepatitis B infection.

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg Tablet Preface :


Chronic infection with Hepatitis B Virus (HBV) constitutes a major global public health problem despite the availability of a prophylactic vaccine.
Hepatitis B infections are the notable causes for disease burden such as liver cirrhosis and Hepatocellular Carcinoma (HCC) .
Tafnat 25mg (Tenofovir Alafenamide -TAF) tablets diagnosis of HBV infections and its associated 2 diseases are mainly based on a constellation of clinical, biochemical, histological and serological findings. The persistence of serum Hepatitis B.
Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg (Tenofovir Alafenamide) is added as a new drug to the list of recommendations for the treatment of CHB.
Tafnat 25mg (Tenofovir Alafenamide -TAF) Tablets (TAF has) pharmacology similar to TDF with a higher cell delivery to hepatocytes but less systemic exposure.
“FDA has approved Tafnat 25mg (Tenofovir alafenamide -TAF) (tenofovir alafenamide) once daily for the treatment of chronic HBV infection in adults with compensated liver disease”.

Mechanism of Action :


Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg (TAF) is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) and a novel ester prodrug of the antiretroviral,tenofovir.
Following oral administration, Tafnat 25mg (Tenofovir alafenamide -TAF) (TAF) is converted in vivo to tenofovir. An acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Tenofovir alafenamide 25mg Tablets mimics normal DNA building blocks but is lacking a 3'-OH molecule required for phosphodiester bond linkage.
A competing TAF with regular nucleotides for incorporation into the proviral DNA and prevention of the formation of 5 to 3 tenofovir tablets. A phosphodiester linkage required for DNA elongation.
Tafnat 25mg (Tenofovir Alafenamide -TAF) tablets causes early chain termination and prevents proviral DNA 27 transcription.

Pharmacokinetics :

The Pharmacokinetic properties of Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg (TAF) are given below. The multiple dose PK parameters of Tafnat 25mg (Tenofovir alafenamide -TAF) 25mg Tablet (TAF) and 28 its metabolite, Tenofovir,are provided in Table 3.

Tafnat Bio availability :

Tafant 25mg following oral administration, peak plasma concentrations occur approximately 0.48 hours after the dose.

Food :

Administration of a high-fat meal increases Area Under Curve (AUC) by 1.65 folds compared with administration 28 in the fasting state.

Distribution:

Plasma protein binding is 80%.

Metabolism of Tafnat 25mg (Tenofovir alafenamide -TAF) :

Tafnat 25mg (Tenofovir alafenamide -TAF) requires initial hydrolysis for intracellular conversion to tenofovir and subsequent phosphorylation by cellular enzymes to form the active metabolite, tenofovir diphosphate.
Tafnat first hydrolyzed in hepatocytes and cathepsin A in Peripheral Blood Mononuclear Cells (PBMCs) and macrophages BY THE METHOD OF intracellular , Carboxylesterase 1 (CES1)
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet Only minimally metabolized by CYP3A.

Contraindications:

There are no contraindication reported with Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF)

TAFNAT Warnings and Precautions :

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. Treatment with Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity .

Post Treatment Exacerbation of Hepatitis B Infection :

Discontinuation of Tafnat25mg (Tenofovir Alafenamide Fumarate -TAF) may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue of (Tenofovir alafenamide -TAF) tablets.

Risk of Development of HIV-1 Resistance in Patients Co-infected with HBV and HIV-1 :

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) alone is not recommended for the treatment of HIV-1 infection, as there is a risk of development of HIV-1 resistance. In patients co-infected with HBV and HIV-1, efficacy of TAF has not been established. Prior to initiating the therapy with Tafnat 25mg (Tenofovir Alafenamide -TAF) in patients with HBV-HIV co-infected patients, HIV antibody testing should be offered and, if positive, an appropriate antiretroviral combination regimen that is recommended for patients coinfected with HIV-1 should be used.

Indications and Usage :

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) is indicated for the treatment of chronic HBV infection in adults with compensated liver disease.
Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) Tablet Dosage Forms and Composition :
Composition: Each Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) tablet contains 25 mg of tenofovir alafenamide WHICH IS equivalent to 28 mg of Tenofovir Alafenamide Fumarate).
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet includes the following inactive ingredients.
Croscarmellose sodium,lactose monohydrate, magnesium stearate and microcrystalline cellulose.
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet is film coated with a coating material containing. Iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium 28 dioxide.

Storage and Handling :

• 28 Store below 30°C (86°F).
• Keep container tightly closed.
• Dispense only in original container.

TAFNAT

Bio availability :

Tafant 25mg following oral administration, peak plasma concentrations occur approximately 0.48 hours after the dose.

Food :

Administration of a high-fat meal increases Area Under Curve (AUC) by 1.65 folds compared with administration 28 in the fasting state.

Contraindications:

There are no contraindication reported withTafnat 25mg (Tenofovir alafenamide -TAF)

CONTACT US

TAFNAT

Tafnat (Tenofovir Alafenamide -TAF) 25mg Tablet Brand Name: Tafnat
Composition: Tenofovir Alafenamide (TAF) 25mg
Packing: Pack of 30 Tablets

Chronic infection with Hepatitis B Virus (HBV) constitutes a major global public health problem despite the availability of a prophylactic vaccine.
Hepatitis B infections are the notable causes for disease burden such as liver cirrhosis and Hepatocellular Carcinoma (HCC) .

OUR ADDRESS

WE CAN HELP YOU

+91 - 99404 72902

millionhealthpharmaceuticals@gmail.com
                  info@tafnat.com

Pedariyar Kovil Street, Seven Wells,
                 Chennai - 600 001. Tamilnadu, India.